STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation
Running, not enrolling · Not applicable
Conditions studied: Atrial Fibrillation
In brief
The objective of this study is to compare the efficacy of three different ablation strategies in patients with persistent AF: 1. PV antral isolation alone (PVAI) 2. PV antral isolation plus ablation of drivers (PVAI+drivers) 3. PV antral isolation plus isolation of posterior wall (PVAI+box) All three strategies will employ contemporary catheter ablation technology using more efficient open irrigated tip cooling and contact force sensing.
Key facts
- Study ID
- NCT04428944
- Run by
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- People needed
- 617
- Starts
- 2021-06-01
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2026-05-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients 18 years of age or older
- Patients undergoing first-time ablation procedure for AF
- Patients with persistent AF defined as a sustained episode more than 3 months but less than three years
- Patients with symptomatic AF - symptomatic patients are those who have been aware of their AF at any time within the last 5 years prior to enrolment. Symptoms may include, but are not restricted to, palpitations, shortness of breath, chest pain, fatigue, left ventricular dysfunction, or other symptoms or any combination of the above
- Patients whose AF has been refractory to at least one antiarrhythmic drug
- At least one episode of AF must have been documented by ECG, holter, loop recorder, telemetry, trans-telephonic monitor or implanted device within the last 2 years from enrolment
- Patients must be able and willing to provide written informed consent to participate in the study
You may not qualify if…
- Patients with paroxysmal AF (no episodes lasting > 7 days)
- Patients with early persistent AF, sustained episode ≤ 3 months
- Patients with very long lasting persistent AF (episodes lasting > 3 years)
- Patients with CHA2DS2-VASc score of 0.
- Patients for whom cardioversion or sinus rhythm will never be attempted/pursued
- Patients with AF felt to be secondary to an obvious reversible cause
- Patients with contraindication to oral anticoagulation or systemic anticoagulation with heparin
- Patients with left atrial diameter > 60 mm in the parasternal long axis view
- Patients who are pregnant
Where it is running
- Brigham & Women'S Hosptial Inc. — Boston, Massachusetts, United States
- Canberra Heart Rhythm Foundation — Garran, Australian Capital Territory, Australia
- Royal Adelaide Hospital and Cardiovascular Centre — Adelaide, Australia
- Alfred Health — Melbourne, Australia
- Royal Melbourne Hospital — Parkville, Australia
- Medical University of Graz — Graz, Austria
- Ordensklinikum Linz GmbH — Linz, Austria
- OLV Hospital Aalst — Aalst, Belgium
- Antwerp University Hospital (UZA) — Edegem, Belgium
- AZ Sint-Jan — Ruddershove, Belgium
- University of Calgary Foothills — Calgary, Alberta, Canada
- Vancouver General Hospital — Vancouver, British Colombia, Canada
- St. Paul's Hospital, Vancouver, BC — Vancouver, British Colombia, Canada
- Royal Jubilee Hospital — Victoria, British Colombia, Canada
- Hamilton General Hospital — Hamilton, Ontario, Canada
- Southlake Regional Health Center — Newmarket, Ontario, Canada
- Laurent Macle — Montreal, QC - Québec, Canada
- MUHC, McGill University Health Centre — Montreal, Quebec, Canada
- University of Ottawa Heart Institute — Ottawa, Quebec, Canada
- Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) — Québec, Quebec, Canada
- Hôpital Fleurimont, CHUS — Sherbrooke, Quebec, Canada
- Hospital St-Joseph — Marseille, France
- Institut Mutualiste Montsouris — Paris, France
- Clinique du Tonkin — Villeurbanne, France
- Ospedale Generale Regionale F. Miulli — Acquaviva delle Fonti, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.